• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

致癌基因 MYC 的失调导致代谢重编程,这是癌症治疗的一个有吸引力的靶点。

Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers.

机构信息

Department of Bioinformatics, Faculty of Medicine, Semmelweis University, 1094 Budapest, Hungary.

Institute of Enzymology, Research Centre for Natural Sciences, Eötvös Loránd Research Network, 1117 Budapest, Hungary.

出版信息

Cells. 2023 Jun 29;12(13):1745. doi: 10.3390/cells12131745.

DOI:10.3390/cells12131745
PMID:37443779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10341379/
Abstract

MYC is one of the most deregulated oncogenes on multiple levels in cancer. As a node transcription factor, MYC plays a diverse regulatory role in many cellular processes, including cell cycle and metabolism, both in physiological and pathological conditions. The relentless growth and proliferation of tumor cells lead to an insatiable demand for energy and nutrients, which requires the rewiring of cellular metabolism. As MYC can orchestrate all aspects of cellular metabolism, its altered regulation plays a central role in these processes, such as the Warburg effect, and is a well-established hallmark of cancer development. However, our current knowledge of MYC suggests that its spatial- and concentration-dependent contribution to tumorigenesis depends more on changes in the global or relative expression of target genes. As the direct targeting of MYC is proven to be challenging due to its relatively high toxicity, understanding its underlying regulatory mechanisms is essential for the development of tumor-selective targeted therapies. The aim of this review is to comprehensively summarize the diverse forms of MYC oncogenic deregulation, including DNA-, transcriptional- and post-translational level alterations, and their consequences for cellular metabolism. Furthermore, we also review the currently available and potentially attractive therapeutic options that exploit the vulnerability arising from the metabolic rearrangement of MYC-driven tumors.

摘要

MYC 是癌症中多个层面上最失调的癌基因之一。作为一个节点转录因子,MYC 在许多细胞过程中发挥着多样化的调节作用,包括细胞周期和代谢,无论是在生理还是病理条件下。肿瘤细胞的无休止生长和增殖导致对能量和营养的无止境需求,这需要对细胞代谢进行重新布线。由于 MYC 可以协调细胞代谢的各个方面,其改变的调节在这些过程中起着核心作用,例如沃伯格效应,并且是癌症发展的一个既定标志。然而,我们目前对 MYC 的了解表明,其对肿瘤发生的空间和浓度依赖性贡献更多地取决于靶基因的整体或相对表达的变化。由于直接针对 MYC 由于其相对较高的毒性而被证明具有挑战性,因此了解其潜在的调节机制对于开发肿瘤选择性靶向治疗至关重要。本综述的目的是全面总结 MYC 致癌失调的多种形式,包括 DNA、转录和翻译后水平的改变,以及它们对细胞代谢的影响。此外,我们还回顾了目前可用的和潜在有吸引力的治疗选择,这些选择利用了由 MYC 驱动的肿瘤代谢重排产生的脆弱性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba7/10341379/018b3e752f51/cells-12-01745-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba7/10341379/a36fcce9a788/cells-12-01745-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba7/10341379/018b3e752f51/cells-12-01745-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba7/10341379/a36fcce9a788/cells-12-01745-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba7/10341379/018b3e752f51/cells-12-01745-g002.jpg

相似文献

1
Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers.致癌基因 MYC 的失调导致代谢重编程,这是癌症治疗的一个有吸引力的靶点。
Cells. 2023 Jun 29;12(13):1745. doi: 10.3390/cells12131745.
2
MYC Analysis in Cancer and Evolution.癌症与进化中的 MYC 分析。
Methods Mol Biol. 2021;2318:87-117. doi: 10.1007/978-1-0716-1476-1_6.
3
MYC activation is a hallmark of cancer initiation and maintenance.MYC激活是癌症起始和维持的一个标志。
Cold Spring Harb Perspect Med. 2014 Jun 2;4(6):a014241. doi: 10.1101/cshperspect.a014241.
4
Regulation of cancer cell metabolism: oncogenic MYC in the driver's seat.调控癌细胞代谢:致癌基因 MYC 居功至伟。
Signal Transduct Target Ther. 2020 Jul 10;5(1):124. doi: 10.1038/s41392-020-00235-2.
5
MYC and metabolism on the path to cancer.MYC与癌症发展过程中的新陈代谢
Semin Cell Dev Biol. 2015 Jul;43:11-21. doi: 10.1016/j.semcdb.2015.08.003. Epub 2015 Aug 12.
6
MYC, metabolism, cell growth, and tumorigenesis.MYC、代谢、细胞生长和肿瘤发生。
Cold Spring Harb Perspect Med. 2013 Aug 1;3(8):a014217. doi: 10.1101/cshperspect.a014217.
7
MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.MYC 和 RAF:细胞信号传导中的关键效应因子和人类癌症中的主要驱动因子。
Curr Top Microbiol Immunol. 2017;407:117-151. doi: 10.1007/82_2017_4.
8
MYC in oncogenesis and as a target for cancer therapies.MYC 在肿瘤发生中的作用及其作为癌症治疗靶点。
Adv Cancer Res. 2010;107:163-224. doi: 10.1016/S0065-230X(10)07006-5.
9
MYC, Metabolism, and Cancer.MYC、代谢与癌症。
Cancer Discov. 2015 Oct;5(10):1024-39. doi: 10.1158/2159-8290.CD-15-0507. Epub 2015 Sep 17.
10
Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.c-MYC信号通路在炎症性和癌性结肠疾病中的治疗意义
World J Gastroenterol. 2016 Sep 21;22(35):7938-50. doi: 10.3748/wjg.v22.i35.7938.

引用本文的文献

1
Preliminary Metabolomics Study Suggests Favorable Metabolic Changes in the Plasma of Breast Cancer Patients after Surgery and Adjuvant Treatment.初步代谢组学研究表明,乳腺癌患者术后及辅助治疗后血浆中代谢发生了有益变化。
Biomedicines. 2024 Sep 26;12(10):2196. doi: 10.3390/biomedicines12102196.
2
Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.溴结构域蛋白靶向药物与小细胞肺癌中的 MYC
Curr Cancer Drug Targets. 2024;24(9):930-940. doi: 10.2174/0115680096272757231211113206.

本文引用的文献

1
TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding.TXNIP 的缺失通过增加 Myc 的基因组结合来扩大 Myc 依赖性转录程序。
PLoS Biol. 2023 Mar 17;21(3):e3001778. doi: 10.1371/journal.pbio.3001778. eCollection 2023 Mar.
2
3,3'-Diindolylmethane Augments 5-Fluorouracil-InducedGrowth Suppression in Gastric Cancer Cells through Suppression of the Akt/GSK-3 and WNT/Beta-Catenin.3,3'-二吲哚甲烷通过抑制Akt/GSK-3和WNT/β-连环蛋白增强5-氟尿嘧啶诱导的胃癌细胞生长抑制作用。
J Oncol. 2023 Feb 4;2023:8268955. doi: 10.1155/2023/8268955. eCollection 2023.
3
Synthesis and Biological Evaluation of Potential Oncoimmunomodulator Agents.
潜在的肿瘤免疫调节剂的合成与生物学评价。
Int J Mol Sci. 2023 Jan 30;24(3):2614. doi: 10.3390/ijms24032614.
4
Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue.Omomyc的药代动力学分析显示其在肿瘤组织中具有持久的结构完整性和较长的终末半衰期。
Cancers (Basel). 2023 Jan 29;15(3):826. doi: 10.3390/cancers15030826.
5
c-MYC-Driven Polyamine Metabolism in Ovarian Cancer: From Pathogenesis to Early Detection and Therapy.c-MYC驱动的卵巢癌多胺代谢:从发病机制到早期检测与治疗
Cancers (Basel). 2023 Jan 19;15(3):623. doi: 10.3390/cancers15030623.
6
Downregulation of gene expression in hypoxic cancer cells by an activatable G-quadruplex stabiliser.可激活的G-四链体稳定剂对缺氧癌细胞中基因表达的下调作用
Chem Commun (Camb). 2023 Feb 21;59(16):2247-2250. doi: 10.1039/d2cc06347f.
7
Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes.染色体外 DNA 扩增导致小细胞肺癌异质性并与更差的预后相关。
Cancer Discov. 2023 Apr 3;13(4):928-949. doi: 10.1158/2159-8290.CD-22-0796.
8
Splice-switch oligonucleotide-based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC-driven hepatocellular carcinoma.基于剪接转换寡核苷酸的组合平台确定了针对MYC驱动的肝细胞癌的合成致死靶点CHK1和BRD4。
Bioeng Transl Med. 2022 Sep 3;8(1):e10363. doi: 10.1002/btm2.10363. eCollection 2023 Jan.
9
Multiomics Study of a Novel Naturally Derived Small Molecule, NSC772864, as a Potential Inhibitor of Proto-Oncogenes Regulating Cell Cycle Progression in Colorectal Cancer.新型天然小分子 NSC772864 作为调节结直肠癌细胞周期进展的原癌基因潜在抑制剂的多组学研究
Cells. 2023 Jan 16;12(2):340. doi: 10.3390/cells12020340.
10
c-Myc-IMPDH1/2 axis promotes tumourigenesis by regulating GTP metabolic reprogramming.c-Myc-IMPDH1/2 轴通过调节 GTP 代谢重编程促进肿瘤发生。
Clin Transl Med. 2023 Jan;13(1):e1164. doi: 10.1002/ctm2.1164.